Bausch + Lomb Corporation (BLCO)

Market Cap	5.87B +5.7%
Revenue (ttm)	5.10B +6.5%
Net Income	-360.00M
EPS	-1.02
Shares Out	354.32M
PE Ratio	n/a
Forward PE	21.11
Dividend	n/a
Ex-Dividend Date	n/a

Volume	254,073
Open	16.79
Previous Close	15.92
Day's Range	16.34 - 16.93
52-Week Range	10.45 - 18.92
Beta	0.65
Analysts	Buy
Price Target	18.45 (+11.46%)
Earnings Date	Apr 29, 2026

About BLCO

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during heali...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: May 6, 2022
• Employees: 13,000
• Stock Exchange: NYSE
• Ticker Symbol: BLCO
• Website: https://www.bausch.com

Financial Performance

In 2025, Bausch + Lomb's revenue was $5.10 billion, an increase of 6.47% compared to the previous year's $4.79 billion. Losses were -$360.00 million, 13.6% more than in 2024.

Analyst Summary

According to 12 analysts, the average rating for BLCO stock is "Buy." The 12-month stock price target is $18.45, which is an increase of 11.46% from the latest price.

Price Target

$18.45

(11.46% upside)

Analyst Consensus: Buy